Viewray Inc (NASDAQ:VRAY) – Investment analysts at Cantor Fitzgerald issued their FY2017 earnings per share estimates for Viewray in a note issued to investors on Sunday. Cantor Fitzgerald analyst C. Bijou anticipates that the company will post earnings per share of ($1.03) for the year. Cantor Fitzgerald currently has a “Buy” rating and a $13.00 target price on the stock. Cantor Fitzgerald also issued estimates for Viewray’s FY2018 earnings at ($0.59) EPS.

VRAY has been the topic of a number of other reports. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Mizuho reiterated a “buy” rating and set a $12.00 price objective on shares of Viewray in a research note on Wednesday, October 25th. BidaskClub upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, Northland Securities reiterated a “buy” rating and set a $10.00 price objective on shares of Viewray in a research note on Friday, November 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $11.20.

Viewray (VRAY) opened at $9.13 on Wednesday. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59. Viewray has a one year low of $3.01 and a one year high of $10.39. The stock has a market cap of $607.22, a P/E ratio of -8.38 and a beta of 17.60.

Viewray (NASDAQ:VRAY) last issued its earnings results on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $12.20 million for the quarter, compared to analyst estimates of $18.63 million. The business’s revenue for the quarter was up 2950.0% compared to the same quarter last year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its stake in shares of Viewray by 843.2% during the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after purchasing an additional 14,789 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Viewray by 5.0% during the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock valued at $135,000 after purchasing an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Viewray during the second quarter valued at approximately $159,000. White Pine Capital LLC bought a new position in shares of Viewray during the second quarter valued at approximately $173,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in Viewray in the third quarter valued at approximately $164,000. Hedge funds and other institutional investors own 50.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/brokers-offer-predictions-for-viewray-incs-fy2017-earnings-vray/1800994.html.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with Analyst Ratings Network's FREE daily email newsletter.